微信小陈
微信小章
产品简介
购买须知
| 产品名称： | Panc 10.05 |
|---|---|
| 商品货号： | TS211136 |
| Organism： | Homo sapiens, human |
| Tissue： | pancreas |
| Cell Type： | epithelial |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | adenocarcinoma |
| Age： | adult |
| Gender： | male |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Images： |  |
| Derivation： | Panc 10.05 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. The Panc 10.05 cell line was derived from the same patient as the PL45 cell line (ATCC CRL-2558). |
| Clinical Data： | adult
male
|
| Antigen Expression： | MHC class I +; MHC class II - |
| Oncogene： | K-ras +
Ref  Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Genes Expressed： | cytokeratins 7 and 18
Ref
Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Cellular Products： | cytokeratins 7 and 18
Ref Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |
| Tumorigenic： | Yes |
| Effects： | Yes, forms tumors in nude or SCID mice |
| Comments： | Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine.
The cells have a reported plating efficiency of 40%.
|
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.xa0
Subculture Ratio: 1:2 to 1:4 Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. |
| Cryopreservation： | Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage Temperature: Liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | D5S818: 13 D13S317: 12 D7S820: 8,9 D16S539: 9,12 vWA: 16 THO1: 6,9.3 Amelogenin: X TPOX: 11 CSF1PO: 12 |
| Population Doubling Time： | 19.2 hrs |
| Name of Depositor： | EM Jaffee |
| Deposited As： | human |
| Year of Origin： | 1992 |
| References： | Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 |